Author Search Results :: Kabale University Library Catalog

1

What is the role of antineoplastic drug safety in reimbursement decision making? by A. S. Kolbin, A. A. Kurylev

Published 2018-11-01

Get full text

Article

Save to List

Saved in:
2

Review of methods for assessing the cost-effectiveness of medical interventions by T. I. Busheva, A. A. Kurylev

Published 2025-01-01

Get full text

Article

Save to List

Saved in:
3

Role of RWD / RWE in health technology assessment by V. G. Borovskaya, A. A. Kurylev

Published 2023-03-01

Get full text

Article

Save to List

Saved in:
4

RETRACTED: ESMO Guidance for reporting oncology real-world evidence (GROW) by A. Sh. Motrinchuk, A. A. Kurylev

Published 2024-04-01

Get full text

Article

Save to List

Saved in:
5

Proposed changes ICER 2023 value assessment framework by I. R. Svechkareva, A. A. Kurylev

Published 2023-12-01

Get full text

Article

Save to List

Saved in:
6

Real-world data studies in oncology: analysis of the Russian publications by V. F. Achikyan, A. A. Kurylev, A. S. Kolbin

Published 2024-04-01

Get full text

Article

Save to List

Saved in:
7

Real-world clinical practice in health technology assessment: state of the art for 2022 by A. A. Kurylev, A. A. Zhuravkov, A. S. Kolbin

Published 2023-01-01

Get full text

Article

Save to List

Saved in:
8

Review of real-world studies on capmatinib use in MET-mutated lung cancer by A. A. Kurylev, A. S. Kolbin, I. R. Svechkareva

Published 2025-04-01

Get full text

Article

Save to List

Saved in:
9

Particular qualities of evaluation of electronic card data in modern healthcare by I. R. Svechkareva, A. A. Kurylev, D. E. Shilova

Published 2025-01-01

Get full text

Article

Save to List

Saved in:
10

HEALTH ECONOMIC ASSESSMENT OF ANTIRHEUMATIC DRUGS IN PATIENTS WITH REUMATHOID ARTHRITIS PROGRESSED AFTER METOTREXATE by A. S. Kolbin, A. A. Kurylev, M. A. Proskurin, Yu. E. Balykina

Published 2016-12-01

Get full text

Article

Save to List

Saved in:
11

CYP2D6 genotyping in the daily routine of a psychiatric hospital – pharmacoeconomic evaluation by A. A. Kurylev, B. V. Andreev, A. S. Kolbin, O. V. Limankin

Published 2018-05-01

Get full text

Article

Save to List

Saved in:
12

The real practice of clinical and economic research of drugs included in the Federal Program of High-Cost Nosologies by A. S. Kolbin, Yu. M. Gomon, A. R. Kasimova, A. A. Kurylev, A. E. Bem

Published 2022-04-01

Get full text

Article

Save to List

Saved in:
13

The socioeconomic burden of meningococcal infection in the Russian Federation by Yu. V. Lobzin, A. S. Kolbin, A. A. Vilnits, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin

Published 2024-12-01

Get full text

Article

Save to List

Saved in:
14

Modeling microbial drug-resistance: from mathematics to pharmacoeconomics by Yu. M. Gomon, M. A. Arepyeva, Yu. E. Balykina, A. S. Kolbin, A. A. Kurylev, M. A. Proskurin, S. V. Sidorenko

Published 2018-05-01

Get full text

Article

Save to List

Saved in:
15

FIRST RUSSIAN TYPE 2 DIABETES MELLITUS SIMULATION MODEL WITH DISCREET EVENTS MODELING. HEALTH-ECONOMIC ANALYSIS by A. S. Kolbin, O. K. Khmelnitskiy, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin, E. P. Kolpak, M. V. Bure

Published 2015-03-01

Get full text

Article

Save to List

Saved in:
16

The social-economic burden of spinal muscular atrophy in Russia by A. S. Kolbin, D. V. Vlodavets, A. A. Kurylev, Yu. Ye. Balykina, M. A. Proskurin, S. A. Mishinova, O. Yu. Germanenko, N. Yu. Kolbina

Published 2021-02-01

Get full text

Article

Save to List

Saved in:
17

ANALYSIS OF CONSUMPTION OF ANTIBACTERIAL DRUGS FOR SYSTEMIC USE IN HOSPITALS OF SAINT PETERSBURG IN 2014–2015 by Yu. M. Gomon, A. A. Kurylev, A. S. Kolbin, M. A. Proskurin, I. G. Ivanov, S. V. Sidorenko, M. A. Arepieva, A. V. Sokolov

Published 2018-10-01

Get full text

Article

Save to List

Saved in:
18

MATHEMATICAL MODEL OF REIMBURSEMENT DECISION MAKING IN RUSSIA. RESULTS OF VIM LIST FOR 2016 by A. S. Kolbin, A. V. Prasolov, E. A. Maksimkina, Yu. E. Balykina, Z. M. Golant, Yu. S. Polushin, A. A. Kurylev, I. A. Vilyum

Published 2016-04-01

Get full text

Article

Save to List

Saved in:
19

Pharmacogenetics of schizophrenia in real clinical practice: a clinical case by R. F. Nasyrova, N. A. Schnaider, K. O. Mironov, G. A. Shipulin, O. P. Dribnokhodova, E. A. Golosov, M. Yu. Tolmachev, B. V. Andreev, A. A. Kurylev, L. Sh. Akhmetova, О. V. Limankin, N. G. Neznanov

Published 2018-12-01

Get full text

Article

Save to List

Saved in:

What is the role of antineoplastic drug safety in reimbursement decision making? by A. S. Kolbin, A. A. Kurylev

Review of methods for assessing the cost-effectiveness of medical interventions by T. I. Busheva, A. A. Kurylev

Role of RWD / RWE in health technology assessment by V. G. Borovskaya, A. A. Kurylev

RETRACTED: ESMO Guidance for reporting oncology real-world evidence (GROW) by A. Sh. Motrinchuk, A. A. Kurylev

Proposed changes ICER 2023 value assessment framework by I. R. Svechkareva, A. A. Kurylev

Real-world data studies in oncology: analysis of the Russian publications by V. F. Achikyan, A. A. Kurylev, A. S. Kolbin

Real-world clinical practice in health technology assessment: state of the art for 2022 by A. A. Kurylev, A. A. Zhuravkov, A. S. Kolbin

Review of real-world studies on capmatinib use in MET-mutated lung cancer by A. A. Kurylev, A. S. Kolbin, I. R. Svechkareva

Particular qualities of evaluation of electronic card data in modern healthcare by I. R. Svechkareva, A. A. Kurylev, D. E. Shilova

HEALTH ECONOMIC ASSESSMENT OF ANTIRHEUMATIC DRUGS IN PATIENTS WITH REUMATHOID ARTHRITIS PROGRESSED AFTER METOTREXATE by A. S. Kolbin, A. A. Kurylev, M. A. Proskurin, Yu. E. Balykina

CYP2D6 genotyping in the daily routine of a psychiatric hospital – pharmacoeconomic evaluation by A. A. Kurylev, B. V. Andreev, A. S. Kolbin, O. V. Limankin

The real practice of clinical and economic research of drugs included in the Federal Program of High-Cost Nosologies by A. S. Kolbin, Yu. M. Gomon, A. R. Kasimova, A. A. Kurylev, A. E. Bem

The socioeconomic burden of meningococcal infection in the Russian Federation by Yu. V. Lobzin, A. S. Kolbin, A. A. Vilnits, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin

Modeling microbial drug-resistance: from mathematics to pharmacoeconomics by Yu. M. Gomon, M. A. Arepyeva, Yu. E. Balykina, A. S. Kolbin, A. A. Kurylev, M. A. Proskurin, S. V. Sidorenko

FIRST RUSSIAN TYPE 2 DIABETES MELLITUS SIMULATION MODEL WITH DISCREET EVENTS MODELING. HEALTH-ECONOMIC ANALYSIS by A. S. Kolbin, O. K. Khmelnitskiy, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin, E. P. Kolpak, M. V. Bure

The social-economic burden of spinal muscular atrophy in Russia by A. S. Kolbin, D. V. Vlodavets, A. A. Kurylev, Yu. Ye. Balykina, M. A. Proskurin, S. A. Mishinova, O. Yu. Germanenko, N. Yu. Kolbina

ANALYSIS OF CONSUMPTION OF ANTIBACTERIAL DRUGS FOR SYSTEMIC USE IN HOSPITALS OF SAINT PETERSBURG IN 2014–2015 by Yu. M. Gomon, A. A. Kurylev, A. S. Kolbin, M. A. Proskurin, I. G. Ivanov, S. V. Sidorenko, M. A. Arepieva, A. V. Sokolov

MATHEMATICAL MODEL OF REIMBURSEMENT DECISION MAKING IN RUSSIA. RESULTS OF VIM LIST FOR 2016 by A. S. Kolbin, A. V. Prasolov, E. A. Maksimkina, Yu. E. Balykina, Z. M. Golant, Yu. S. Polushin, A. A. Kurylev, I. A. Vilyum

Pharmacogenetics of schizophrenia in real clinical practice: a clinical case by R. F. Nasyrova, N. A. Schnaider, K. O. Mironov, G. A. Shipulin, O. P. Dribnokhodova, E. A. Golosov, M. Yu. Tolmachev, B. V. Andreev, A. A. Kurylev, L. Sh. Akhmetova, О. V. Limankin, N. G. Neznanov

Search Tools: